Оne of the largest medicine manufacturers in Russia, Binnopharm Group was created in 2020 through consolidation of pharmaceutical assets of Sistema. The Group boasts five plants, which produce an extensive range of prescription and OTC medicines. The Group has over 450 marketing authorisations in Russia, more than 100 medicines included in in the List of Vital and Essential Medicines. With five plants across Russia, Binnopharm Group has the largest area of medicine production capacity in Russia. Binnopharm Group facilities manufacture medicines in all dosage forms, from tablets and capsules to sprays, injections, and suppositories. 20% of the products are made from the Group’s own active pharmaceutical ingredients. Binnopharm Group medicines are procured under government tenders, sold in the retail pharmaceutical market, and also exported to 14 countries worldwide. The Group is one of the largest suppliers for the inpatient segment, providing clinics and hospitals with antibiotics in various dosage forms; medicines for endocrinology, neurology, cardiology and other therapeutic groups; and medical devices for blood transfusion. Binnopharm Group makes high-quality, effective and safe medical products and adhering to GMP standards. The Group’s products are also available in 14 countries. Official representative offices of Binnopharm Group have been opened in 6 CIS countries and China. Binnopharm Group constantly develops new products and expands its portfolio. In 2023 the Group opens an advanced R&D center in Russia, with a total floor area of 12,000 sq m. By 2025, Binnopharm Group is set to market over 100 medical products for such disease areas as dermatology, neurology, gynaecology, paediatrics, etc. Human capital development along with constant upgrades of production capacities, improvement of R&D competencies, and adherence to the world's top quality control standards is what underpins Binnopharm Group’s operations.